2. Neuronal Signaling Epigenetics
  3. Monoamine Oxidase Histone Demethylase
  4. Tranylcypromine hemisulfate

Tranylcypromine hemisulfate  (Synonyms: SKF 385 hemisulfate)

Cat. No.: HY-B1496 Purity: 99.94%
COA
SDS
Handling Instructions Technical Support

Tranylcypromine (SKF 385) hemisulfate is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hemisulfate is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Tranylcypromine has antidepressant effects.

For research use only. We do not sell to patients.

CAS No. : 13492-01-8

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of Tranylcypromine hemisulfate:

Tranylcypromine hemisulfate Related Antibodies

Top Publications Citing Use of Products

    Tranylcypromine hemisulfate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jun 23:117073.  [Abstract]

    Schematic diagram of Triflupromazine and Tranylcypromine hydrochloride alleviate primary cisplatin resistance in lung adenocarcinoma by promoting LDHA-mediated AMBRA1 ubiquitination. LDHA interacts with AMBRA1 via non-metabolic enzyme functions, promoting AMBRA1 ubiquitination and degradation, which leads to cisplatin resistance by regulating the cell cycle and apoptosis.

    Tranylcypromine hemisulfate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jun 23:117073.  [Abstract]

    Tranylcypromine hydrochloride (0-100 μM) significantly inhibited LDHA expression and increased AMBRA1 protein levels in resistant cell line H1838.

    Tranylcypromine hemisulfate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jun 23:117073.  [Abstract]

    CCK8 assay evaluating the survival of H1838 treated with serial concentrations of cisplatin in combination with Tranylcypromine hydrochloride (0-100 μM, 48 h).

    Tranylcypromine hemisulfate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jun 23:117073.  [Abstract]

    Apoptosis analysis in H1838 cells treated with cisplatin accompanied by TRI (5 μM) and Tranylcypromine hydrochloride (50 μM) respectively for 48 h.

    View All Monoamine Oxidase Isoform Specific Products:

    View All Isoforms
    MAO-A MAO-B

    View All Histone Demethylase Isoform Specific Products:

    View All Isoforms
    KDM1/LSD1 KDM2 KDM3 KDM4 KDM5 KDM6 KDM7

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Tranylcypromine (SKF 385) hemisulfate is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hemisulfate is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Tranylcypromine has antidepressant effects[1][2].

    IC50 & Target

    KDM1/LSD1

     

    In Vitro

    Tranylcypromine (10 nM to 10 μM) exerts neuroprotective effects against toxicity induced by human Aβ(1-42) oligomers independently from the presence of glial cells[1]. Tranylcypromine (100 μM) significantly protects RGCs from glutamate neurotoxicity-induced apoptosis as well as apoptosis induced by oxidative stress. Tranylcypromine promotes mitogen-activated protein kinase 12 (p38 MAPKγ) expression under conditions of glutamate (Glu)-induced stress. Besides, tranylcypromine contributes to RGC survival via alterations of p38 MAPKγ activity[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Tranylcypromine hemisulfate Related Antibodies
    In Vivo

    Tranylcypromine treatment significantly and substantially reduces the lesion size and improves generalized hyperalgesia in a dose-dependent fashion in mice with induced endometriosis. In addition, tranylcypromine treatment results in reduced immunoreactivity to biomarkers of proliferation, angiogenesis, and H3K4 methylation, leading to arrested EMT and lesion growth[2]. Tranylcypromine (500 mM) injection exerts neuroprotective effects within intracellular apoptotic signaling pathways and suppresses morphologic changes in the retina of the rat, suppresses caspase 3 activity and recovers p38 MAPKγ expression in the retina after NMDA-induced injury, and enhances RGC survival after retinal injury via the attenuation of NMDA neurotoxicity[3]. Tranylcypromine (10 μg/g) causes an approximate and significant doubling of labeled cells in the combined brain regions examined, as detected by BrdU immunohistochemistry. Tranylcypromine causes the greatest increase in cell proliferation in the cerebellum[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    182.23

    Formula

    C9H12NO2S0.5
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    N[C@H]1[C@H](C2=CC=CC=C2)C1.[0.5H2SO4]
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    H2O : 12.5 mg/mL (68.59 mM; Need ultrasonic)

    DMSO : 5 mg/mL (27.44 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.4876 mL 27.4379 mL 54.8757 mL
    5 mM 1.0975 mL 5.4876 mL 10.9751 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 20 mg/mL (109.75 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation

    Purity: 99.94%

    SDS (480 KB)

    COA (252 KB) HNMR (131 KB) LCMS (250 KB)

    Handling Instructions (2659 KB)
    References
    Animal Administration
    [3]

    Briefly, the rats are anesthetized with an intraperitoneal injection of a 1:1 mixture of xylazine hydrochloride (4 mg/kg) and ketamine hydrochloride (10 mg/kg). Then, the pupil is dilated with phenylephrine hydrochloride and tropicamide eye drops, and 20 nmol NMDA with or without tranylcypromine is injected into the vitreous cavity. To assess the inhibitory effect of mitogen-activated protein kinase (MAPK), 100 nmol BIRB796 is intravitreally injected at the same time of NMDA injection. The injections are performed under a microscope using a 33-gauge needle connected to a microsyringe; the needle is inserted approximately 1.0 mm behind the corneal limbus. Next, either PBS (vehicle control) or 500 mM tranylcypromine (1000 nmol) mixed with 10 mM NMDA (20 nmol) in a total volume of 2.0 μL is injected into the vitreous cavity.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 5.4876 mL 27.4379 mL 54.8757 mL 137.1893 mL
    5 mM 1.0975 mL 5.4876 mL 10.9751 mL 27.4379 mL
    10 mM 0.5488 mL 2.7438 mL 5.4876 mL 13.7189 mL
    15 mM 0.3658 mL 1.8292 mL 3.6584 mL 9.1460 mL
    20 mM 0.2744 mL 1.3719 mL 2.7438 mL 6.8595 mL
    25 mM 0.2195 mL 1.0975 mL 2.1950 mL 5.4876 mL
    H2O 30 mM 0.1829 mL 0.9146 mL 1.8292 mL 4.5730 mL
    40 mM 0.1372 mL 0.6859 mL 1.3719 mL 3.4297 mL
    50 mM 0.1098 mL 0.5488 mL 1.0975 mL 2.7438 mL
    60 mM 0.0915 mL 0.4573 mL 0.9146 mL 2.2865 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Tranylcypromine hemisulfate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Tranylcypromine hemisulfate13492-01-8SKF 385 hemisulfateMonoamine OxidaseHistone DemethylaseMAOInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tranylcypromine hemisulfate
    Cat. No.:
    HY-B1496
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB) Italian - IT (480 KB) Korean - KR (480 KB) Portuguese - PT (480 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.